You've learned that you have diffuse large B-cell lymphoma (DLBCL). What happens now? A cancer diagnosis can feel overwhelming. You might not know what to do first. Start by having a conversation ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments. The drug will be ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse large B-cell lymphoma (DLBCL ... meaning that treatment can begin soon ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...